- Addendum
- 10.1016/j.clinthera.2025.07.019
Corrigendum to "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab" [Clin Ther. 2024;46:916-926
- Oct 01, 2025
- Clinical therapeutics
- Barbara Vogg + 8 more +8
Publications from 2021 to 2026
Showing 10 of 43 papers
Corrigendum to "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab" [Clin Ther. 2024;46:916-926
Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA).
GP2015 is an etanercept biosimilar. Equivalent efficacy and comparable safety of GP2015 to reference etanercept (ref-ETN) was demonstrated in two phase III studies, one in patients with moderate-to-severe chronic plaque-type psoriasis (PsO; EGALITY study) and the other in patients with rheumatoid arthritis (RA; EQUIRA study). EGALITY also included patients with reported psoriatic arthritis (PsA). Here, patient-reported outcome (PRO) data from both studies are presented. EGALITY included 531 patients with PsO and EQUIRA included 376 patients with RA. InEGALITY, patients who had achieved ≥50% improvement in Psoriasis Area and Severity Index (PASI) at week 12 either continued the initial treatment or underwent three treatment switches between GP2015 and ref-ETN starting at week 12. In EQUIRA, patients with at least moderate European League Against Rheumatism response at week 24 received GP2015 up to week 48. Assessed PROs included Dermatology Life Quality Index (DLQI) and EuroQol five-dimension health status questionnaire (EQ-5D-5L) in EGALITY, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score in EQUIRA, and Health Assessment Questionnaire-Disability Index (HAQ-DI) in both studies. In EGALITY, mean DLQI decreased from baseline in the GP2015 and ref-ETN groups, and the mean (standard deviation [SD]) percent reductions from baseline in DLQI were comparable between groups at week 12 (GP2015, - 67.7 [40.7]; ref-ETN, - 67.3 [30.6]), and were sustained after the switch at week 52 ('continued GP2015,' - 77.3 [36.5]; 'continued ref-ETN,' - 72.8 [33.7]; 'switched GP2015,' -73.9 [37.0]; 'switched ref-ETN,' -78.1 [30.9]). The proportion of patients with EQ-5D-5L scores of 1 ('no problems') improved from baseline to week 52 for all five dimensions and was comparable between treatment groups. In EGALITY, in patients with reported PsA at baseline, mean (SD) HAQ-DI scores decreased from baseline, and scores were comparable between treatment groups at week 12 (GP2015, 0.6 [0.7]; ref-ETN, 0.6 [0.6]) and after switching at week 52 ('continued GP2015,' - 0.4 [0.6]; 'continued ref-ETN,' - 0.4 [0.6]; 'switched GP2015,' - 0.4 [0.6]; 'switched ref-ETN,' - 0.1 [0.4]). In EQUIRA, the proportion of patients achieving HAQ-DI in normal range (≤0.5) was comparable between treatment groups up to week 48 ('continued GP2015,' 36.7%; 'switched to GP2015,' 39.9%). The mean FACIT-Fatigue scores increased from baseline and the mean (SD) percent change from baseline in FACIT-Fatigue score at week 24 was 9.6 (9.5) in the 'continued GP2015' and 11.4 (9.7) in the 'switched to GP2015' groups; the scores were sustained after switching until week 48. Treatment with GP2015 and ref-ETN resulted in similar improvements in PROs and quality-of-life scores across the three diseases, namely RA, PsA, and PsO. These improvements were sustained after switching, with consistent benefit on PROs during the treatment period. ClinicalTrials.gov identifiers: NCT01891864, NCT02638259.
Read moreAssessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary.
Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)
Introduction: LEAN is a prospective, multicenter, noninterventional, German cohort study in patients with locally advanced and metastatic hormone-sensitive prostate cancer (PC). This analysis explores the efficacy and safety of leuprorelin in patients with PC and an indication for androgen deprivation therapy (ADT) in routine practice. Methods: Safety assessment focused on the incidence of major adverse cardiovascular (CV) events (MACEs; a composite of all-cause death, myocardial infarction, or stroke) over the 12-month study period. Patients initiating ADT before enrollment were excluded from the analysis. Results: Of the 1,372 patients included, MACEs occurred in 57 (4.2%) patients and in 18/532 (3.4%) versus 39/840 (4.6%) patients without and with a pre-existing CV comorbidity, respectively (p = 0.264). Of the 57 MACEs, 17 were CV events and 20 were considered PC-related events; in 20 patients, events were classed as “other” or the context remained unknown. Only one MACE, nonserious arrhythmia, was considered drug related by the urologist. Of the 52 deaths reported in patients with MACEs, 12 were related to a CV event and 20 were related to disease progression. Conclusion: In a large European patient cohort, leuprorelin-based ADT demonstrated an acceptable safety profile, with a low incidence of CV events.
Read moreSignal-to-noise ratio to assess magnitude, kinetics and impact on pharmacokinetics of the immune response to an adalimumab biosimilar.
Background: The antidrug antibody (ADA) signal-to-noise (S/N) ratio was explored as a novel immunogenicity measure to evaluate the immune response of healthy subjects to a single dose of GP2017, an adalimumab biosimilar. Methodology/results: Bioanalytical methods used for the analysis of ADA S/N ratios and ADA titers were validated for sensitivity, precision and drug interference. ADA S/N ratios strongly correlated with ADA titers. Correlations between ADA area under the curve and ADAmax and pharmacokinetics (PK) were stronger for ADA S/N ratio than for ADA titers. Conclusion: ADA S/N ratio allowed for a more sensitive evaluation of the magnitude and kinetics of the immune response, was better correlated with adalimumab PK and was superior to ADA titers in assessing the impact of the immune response on PK.
Read moreNeudefinition und Messung der Grenzschichtdicke an einer angeströmten Fläche – Ermittlung thermodynamischer und aerodynamischer Größen hieraus
Abstract In dieser Publikation werden die theoretische Grundlage sowie eine Messeinrichtung beschrieben, um den konvektiven Wärmeübergangskoeffizienten sowie die Scherspannung an einer angeströmten Wand zu messen. Hierzu misst das Convective Heattransfer Meter (CHM) den Temperaturabfall innerhalb der Strömungsgrenzschicht.Für exponentiell ablaufende zeitliche Prozesse ist die Zeitkonstante τ definiert als diejenige Zeitspanne, nach welcher eine Größe A(t) auf das 1/e‐fache des Ursprungswerts abgefallen ist, mit der Euler‐Zahl e = 2,718… Analog hierzu wird in diesem Beitrag für räumliche Prozesse mit exponentieller Annäherung anstelle der Zeitkonstanten τ die Grenzschichtdicke d vorgeschlagen. Ein solcher Prozess liegt im viskosen Grenzschichtbereich einer angeströmten Wand vor. Dabei erfährt die parallel zur Wandoberfläche verlaufende Strömung U(y) aufgrund der Viskosität der Luft und der Reibung der Wandoberfläche eine Abbremsung bis hin zur Haftbedingung an der Wandoberfläche. Die neu definierte Grenzschichtdicke d ist jener Abstand von der Wand y = d, für den gilt, dass die lokale Strömungsgeschwindigkeit U(y=d) auf das (1–e–1)‐fache der makroskopischen Strömungsgeschwindigkeit U(y=∞) angestiegen ist.Im Unterschied zur oft verwendeten Grenzschichtdicke δ, für die die Schwelle definitionsgemäß bei 99 % von U(y=∞) liegt, bietet die Neudefinition der Grenzschichtdicke d Vorteile hinsichtlich deren Messbarkeit sowie der Ermittlung der konvektiven Wärmeübertragung und der Ermittlung der Scherspannung an angeströmten Körpern.
Read moreEffet en vie réelle, sécurité et données rapportées par les patients atteints de rhumatismes inflammatoires chroniques traités par le biosimilaire de l’étanercept GP2015 : résultats de l’étude COMPACT
S1057 A Randomized Phase I Study Comparing Pharmacokinetics, Safety and Immunogenicity of High Concentration Formulation (100 mg/mL) With GP2017 Formulation (50 mg/mL), an Adalimumab Biosimilar, in Healthy Male Subjects
Introduction: GP2017 (adalimumab-adaz) is an approved biosimilar of adalimumab (ADL)1, with a concentration of 50 mg/mL. A high-concentration formulation (HCF) (100 mg/mL) can reduce the injection volume, and consequently decrease the number of injections required for patients who need to administer a higher dose. A phase I study (randomized, double-blind, parallel, 2-arm study with healthy male subjects) was conducted to demonstrate pharmacokinetics (PK) comparability between a newly developed GP2017 citrate-free -HCF and the currently approved GP2017. Methods: Healthy male subjects were randomized to receive a single 40 mg s.c. injection of either GP2017 or GP2017-HCF. PK, safety, and immunogenicity were assessed over 72 days post-injection. Primary endpoints were maximum serum concentration (Cmax), area under the concentration–time curve from time zero to infinity (AUC0–inf) and area under the concentration–time curve from time zero to 360 hours (AUC0-360); area under the concentration–time curve from time zero to the last quantifiable concentration (AUC0–last) was assessed as a secondary endpoint. PK comparability was concluded when the 90% confidence intervals (CIs) of the ratios of geometric means were within the predefined comparability margin of 0.80 to 1.25. Results: 331 subjects were randomized, of which 330 received study treatment (162 GP2017-HCF; 168 GP2017). The 90% CI of the ratios (GP2017-HCF / GP2017) of geometric means for the PK endpoints (Cmax, AUCinf, AUC0-360 and AUC0–last) were all contained within the pre-defined comparability limits of 0.80 to 1.25 (Figure). Safety was similar across groups (Table). The numbers and proportions of subjects with positive anti-drug antibodies (ADA) and with neutralizing antibodies (NAb) were comparable overall (up to day 72: GP2017-HCF 69.1% / 63%; GP2017 64.9% / 61.3%, respectively) and at all individual visits. Conclusion: PK comparability between GP2017-HCF and GP2017 was demonstrated, supporting the development of the new formulation of GP2017. Safety and immunogenicity profiles were comparable between treatment groups and consistent with previously reported adalimumab data.Figure 1.: Forest plot to compare primary and secondary PK endpoints between the treatment groups Table 1. - TEAEs by primary system organ class (at least 2% of subjects in any treatment group) Primary system organ classPreferred term GP2017-HCFN=162n (%) GP2017N=168n (%) Number of subjects with at least 1 event 80 (49.4) 95 (56.5) General disorders and administration site conditions 55 (34.0) 69 (41.1) Investigations 16 (9.9) 24 (14.3) Musculoskeletal and connective tissue disorders 8 (4.9) 14 (8.3) Nervous system disorders 8 (4.9) 6 (3.6) Skin and subcutaneous tissue disorders 10 (6.2) 4 (2.4) Gastrointestinal disorders 8 (4.9) 3 (1.8) Respiratory, thoracic and mediastinal disorders 2 (1.2) 6 (3.6) Eye disorders 1 (0.6) 4 (2.4) Injury, poisoning and procedural complications 4 (2.5) 1 (0.6)
Read more553P Innovative medicinal products and early access provision: Challenges and opportunities to improve access to care for oncology patients
A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials